{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:27:05Z","timestamp":1787041625144,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017291","name":"Zhongshan Science and Technology Bureau","doi-asserted-by":"publisher","award":["CXTD2023009"],"award-info":[{"award-number":["CXTD2023009"]}],"id":[{"id":"10.13039\/501100017291","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011198","name":"State Key Laboratory of Drug Research","doi-asserted-by":"publisher","award":["SIMM0120231001"],"award-info":[{"award-number":["SIMM0120231001"]}],"id":[{"id":"10.13039\/501100011198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013152","name":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013152","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2025ZD1800100"],"award-info":[{"award-number":["2025ZD1800100"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119072","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:22:41Z","timestamp":1781763761000},"page":"119072","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Structure-guided discovery of 1H-pyrazolo[3,4-c]pyridin-3-amines as a novel class of hematopoietic progenitor kinase 1 (HPK1) inhibitors"],"prefix":"10.1016","volume":"317","author":[{"given":"Huanyu","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiu","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9776-8136","authenticated-orcid":false,"given":"Bing","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119072_bib1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2026.119072_bib2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119072_bib3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.119072_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.119072_bib5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","article-title":"The foundations of immune checkpoint blockade and the ipilimumab approval decennial","volume":"21","author":"Korman","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119072_bib6","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s41573-022-00538-9","article-title":"The expanding role for small molecules in immuno-oncology","volume":"21","author":"Offringa","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119072_bib7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/bs.ai.2015.09.006","article-title":"MAP4K family kinases in immunity and inflammation","volume":"129","author":"Chuang","year":"2016","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.ejmech.2026.119072_bib8","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.55122","article-title":"A perspective on HPK1 as a novel immuno-oncology drug target","volume":"9","author":"Sawasdikosol","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2026.119072_bib9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/ni1416","article-title":"Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell\u2013mediated immune responses","volume":"8","author":"Shui","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2026.119072_bib10","doi-asserted-by":"crossref","first-page":"11037","DOI":"10.1074\/jbc.M111.310946","article-title":"Down-regulation of B cell receptor signaling by hematopoietic progenitor Kinase 1 (HPK1)-mediated phosphorylation and ubiquitination of activated B cell linker protein (BLNK)","volume":"287","author":"Wang","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119072_bib11","doi-asserted-by":"crossref","first-page":"34693","DOI":"10.1074\/jbc.M707425200","article-title":"Prostaglandin E activates HPK1 kinase activity via a PKA-dependent pathway","volume":"282","author":"Sawasdikosol","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119072_bib12","doi-asserted-by":"crossref","first-page":"18908","DOI":"10.1074\/jbc.M101485200","article-title":"Involvement of hematopoietic progenitor kinase 1 in T cell receptor signaling","volume":"276","author":"Ling","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119072_bib13","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1128\/MCB.25.6.2364-2383.2005","article-title":"Activation of hematopoietic progenitor kinase 1 involves relocation, autophosphorylation, and transphosphorylation by protein kinase D1","volume":"25","author":"Arnold","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119072_bib14","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1083\/jcb.201103105","article-title":"Release of serine\/threonine-phosphorylated adaptors from signaling microclusters down-regulates T cell activation","volume":"195","author":"Lasserre","year":"2011","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119072_bib15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.celrep.2018.09.012","article-title":"The kinase activity of hematopoietic progenitor kinase 1 is essential for the regulation of T cell function","volume":"25","author":"Hernandez","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.119072_bib16","article-title":"Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance","volume":"14","author":"Liu","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119072_bib17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","volume":"25","author":"Roerden","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2026.119072_bib30","doi-asserted-by":"crossref","first-page":"22002","DOI":"10.1021\/acs.jmedchem.4c01930","article-title":"Discovery of PF-07265028, A selective small molecule inhibitor of hematopoietic progenitor Kinase 1 (HPK1) for the treatment of cancer","volume":"67","author":"Gallego","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119072_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012064","article-title":"Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockade","volume":"13","author":"Ciccone","year":"2025","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.ejmech.2026.119072_bib32","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1021\/acsmedchemlett.0c00660","article-title":"Discovery of orally active isofuranones as potent, selective inhibitors of hematopoetic progenitor kinase 1","volume":"12","author":"Degnan","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119072_bib33","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/acsmedchemlett.0c00672","article-title":"Identification of potent reverse indazole inhibitors for HPK1","volume":"12","author":"Yu","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119072_bib34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1021\/acsmedchemlett.2c00238","article-title":"Discovery of pyrazolopyridine derivatives as HPK1 inhibitors","volume":"14","author":"Ye","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119072_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115064","article-title":"Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors","volume":"248","author":"Shi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119072_bib36","doi-asserted-by":"crossref","first-page":"17429","DOI":"10.1021\/acs.jmedchem.4c01325","article-title":"Discovery of BAY-405: an azaindole-based MAP4K1 inhibitor for the enhancement of T-Cell immunity against cancer","volume":"67","author":"Mowat","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119072_bib37","doi-asserted-by":"crossref","first-page":"21520","DOI":"10.1021\/acs.jmedchem.4c02421","article-title":"Discovery of Pyridine-2-Carboxamides derivatives as potent and selective HPK1 inhibitors for the treatment of cancer","volume":"67","author":"Peng","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119072_bib38","doi-asserted-by":"crossref","first-page":"8065","DOI":"10.1021\/acs.jmedchem.2c00172","article-title":"Hematopoietic Progenitor kinase 1 in Tumor immunology: a medicinal chemistry perspective","volume":"65","author":"Zhu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119072_bib39","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/14728222.2024.2344697","article-title":"Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress","volume":"28","author":"Chen","year":"2024","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2026.119072_bib40","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1158\/1535-7163.MCT-10-0574","article-title":"ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action","volume":"10","author":"Fletcher","year":"2011","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.119072_bib41","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.str.2018.10.025","article-title":"Hematopoietic Progenitor Kinase-1 structure in a domain-swapped dimer","volume":"27","author":"Wu","year":"2019","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2026.119072_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001402","article-title":"Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor","volume":"9","author":"You","year":"2021","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.ejmech.2026.119072_bib43","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.tibs.2017.11.008","article-title":"TCR signaling: mechanisms of initiation and propagation","volume":"43","author":"Courtney","year":"2018","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2026.119072_bib44","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","article-title":"T cell receptor (TCR) signaling in health and disease","volume":"6","author":"Shah","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119072_bib45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41392-024-02080-z","article-title":"Cyclin-dependent protein kinases and cell cycle regulation in biology and disease","volume":"10","author":"Pellarin","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119072_bib46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13008-018-0040-6","article-title":"The functional diversity of Aurora kinases: a comprehensive review","volume":"13","author":"Willems","year":"2018","journal-title":"Cell Div."},{"key":"10.1016\/j.ejmech.2026.119072_bib47","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1021\/acsmedchemlett.1c00096","article-title":"Discovery of diaminopyrimidine carboxamide HPK1 inhibitors as preclinical immunotherapy tool compounds","volume":"12","author":"Vara","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119072_bib48","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1021\/acs.jmedchem.4c02631","article-title":"Discovery and optimization of Pyrazine Carboxamide AZ3246, a selective HPK1 inhibitor","volume":"68","author":"Shields","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119072_bib49","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s12276-020-0435-8","article-title":"Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development","volume":"52","author":"Hwang","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2026.119072_bib50","doi-asserted-by":"crossref","first-page":"10439","DOI":"10.1021\/acs.jmedchem.5c00762","article-title":"Structure-Guided optimization of 2-Aminoquinazoline hematopoietic progenitor kinase 1 inhibitors for improved oral bioavailability and synergistic antitumor immunity","volume":"68","author":"Wan","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119072_bib51","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","article-title":"The JAK-STAT pathway at 30:Much learned, much more to do","volume":"185","author":"Philips","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119072_bib52","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1016\/j.apsb.2024.09.008","article-title":"Emerging interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors or degraders as therapeutic agents for autoimmune diseases and cancer","volume":"14","author":"Feng","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.119072_bib53","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12864-019-6344-3","article-title":"Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors","volume":"21","author":"Zhong","year":"2020","journal-title":"BMC Genom."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:00:20Z","timestamp":1787040020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426005179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":41,"alternative-id":["S0223523426005179"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119072","relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv.15002942\/v1","asserted-by":"object"}]},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-guided discovery of 1H-pyrazolo[3,4-c]pyridin-3-amines as a novel class of hematopoietic progenitor kinase 1 (HPK1) inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119072"}}